安徽安科生物工程(集团)股份有限公司 2020 年半年度报告全文 安徽安科生物工程(集团)股份有限公司 2020 年半年度报告 公告编号：2020-048 2020 年 08 月 1 安徽安科生物工程(集团)股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人宋礼华、主管会计工作负责人汪永斌及会计机构负责人(会计主 管人员)迟玲霞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |-----------------------------------------------------------------------------| | | | 报告期内，公司可能存在新药研发不达预期的风险、行业政策紧缩的风险、 | | 招标降价的风险、商誉减值风险、业务整合及规模扩大带来的集团化管理风险、 | | 募集资金使用不达预期的风险、新型冠状病毒肺炎疫情风险等，有关风险 ...

安徽安科生物工程(集团)股份有限公司 2020 年第一季度报告全文 安徽安科生物工程(集团)股份有限公司 2020 年第一季度报告 公告编号：2020-032 2020 年 04 月 1 安徽安科生物工程(集团)股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人宋礼华、主管会计工作负责人汪永斌及会计机构负责人(会计主 管人员)迟玲霞声明：保证季度报告中财务报表的真实、准确、完整。 2 安徽安科生物工程(集团)股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|-------- ...

Financial Performance - The company reported a significant focus on research and development for new drugs and technologies, although specific financial metrics were not detailed in the provided content[3]. - The company's operating revenue for 2019 was ¥1,712,529,669.21, representing a 17.17% increase from ¥1,461,550,203.44 in 2018[15]. - The net profit attributable to shareholders for 2019 was ¥124,465,864.06, a decrease of 52.71% compared to ¥263,171,602.71 in 2018[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥104,536,105.63, down 61.16% from ¥269,143,111.57 in 2018[15]. - The total assets at the end of 2019 were ¥3,226,206,230.51, an increase of 27.67% from ¥2,526,966,294.89 at the end of 2018[15]. - The net assets attributable to shareholders at the end of 2019 were ¥2,626,678,148.09, up 36.78% from ¥1,920,325,638.68 at the end of 2018[15]. - The company reported a basic earnings per share of ¥0.12 for 2019, a decrease of 53.85% from ¥0.26 in 2018[15]. - The company generated a net cash flow from operating activities of ¥295,627,531.92 in 2019, a slight increase of 2.83% from ¥287,490,590.56 in 2018[15]. - The company achieved total operating revenue of 1,712.53 million CNY, a year-on-year increase of 17.17%[27]. - The net profit attributable to ordinary shareholders of the parent company was 124.47 million CNY, a year-on-year decrease of 52.71%[27]. Research and Development - The company has a strategic focus on the biopharmaceutical industry, emphasizing cell engineering, gene engineering, and precision medicine[22]. - The company is developing a full industry chain layout for precision medicine, including gene testing and targeted anti-tumor drug development[22]. - The company has established a comprehensive procurement, R&D, production, logistics, and sales model to ensure independent operational activities[25]. - The R&D strategy focuses on "producing one generation, developing one generation, pre-researching one generation, and reserving one generation," enhancing independent R&D capabilities while collaborating with top domestic research institutions[25]. - The company has established a strong R&D system and is actively collaborating with universities and research institutions to foster innovation[32]. - The company is focusing on innovative drug development, particularly in gene engineering and precision medicine, to enhance its market position[29]. - The company is committed to improving product quality and compliance with GMP management standards to ensure the delivery of safe and effective products[33]. Risk Factors - The company faces risks including unmet expectations in new drug development, tightening industry policies, and potential goodwill impairment[3]. - The company emphasizes the importance of risk factors in its future development outlook, urging investors to be cautious[3]. - The company acknowledges potential goodwill impairment risks from acquisitions, which could negatively affect future earnings[95]. - The company is facing risks from tightening industry regulations that could impact product sales and pricing[94]. - The company is actively managing risks related to bidding price reductions due to national healthcare reforms[95]. Corporate Governance and Structure - The company has multiple wholly-owned subsidiaries and joint ventures, indicating a diversified operational structure[7]. - The company’s legal representative is Song Lihua, highlighting the leadership structure[9]. - The company has a dedicated investor relations team, with contact details provided for inquiries[10]. - The company’s financial report is audited by Rongcheng Accounting Firm, ensuring compliance and accuracy in financial reporting[8]. - The company has established a commitment to ensure that any related transactions are conducted at fair market prices[111]. Shareholder Returns - The company plans to distribute a cash dividend of 1.5 CNY (including tax) for every 10 shares, based on a total of 1,050,298,435 shares[3]. - The company distributed a cash dividend of 1.5 yuan per 10 shares, totaling 157,544,765.25 yuan for the year 2019, which represents 126.58% of the net profit attributable to ordinary shareholders[107]. - The cash dividend policy was executed in compliance with the company's articles of association and shareholder resolutions[101]. - The company has maintained a consistent cash dividend distribution policy over the past three years, with the cash dividends totaling 106,872,210.15 yuan in 2017[107]. - The company’s cash dividends accounted for 100% of the profit distribution in 2019, indicating a strong commitment to returning value to shareholders[103]. Community Engagement and Social Responsibility - The company donated a total of 620,000 RMB in scholarships to various universities during the reporting period[161]. - The company provided 100,000 RMB in scholarships to 19 students from Wenzhou Medical University as part of the "Anke Dream" grassroots employment scholarship program[161]. - The company committed to purchasing agricultural products, including ginger, at prices above the market average to support local farmers[166]. - The company allocated 2.4 million RMB for educational assistance to impoverished students during the reporting period[168]. - The company invested 7.2 million RMB in a poverty alleviation project focused on industrial development[168]. Environmental Compliance - Anke Hengyi reported a total hazardous waste discharge of 20,190 kg, below the approved limit of 28,000 kg, with no instances of exceeding discharge standards[170]. - The company achieved a COD discharge of 90.971 kg, which is within the approved limit of 246.22 kg, with no exceedances reported[171]. - Anke Hengyi's ammonia nitrogen discharge was 1.09 kg, significantly below the limit of 49.244 kg, with no exceedances[171]. - The company has successfully maintained its wastewater treatment facilities, with no exceedances in COD, ammonia nitrogen, and pH levels since August 2018[172]. - The company has implemented an emergency response plan for environmental incidents, which has been filed with the local environmental protection bureau[174]. Investment and Financial Management - The company raised approximately RMB 663.49 million through a non-public stock issuance to specific investors, enhancing its financial resources for future projects[47]. - The company raised a total of RMB 682,039,998.08 through the issuance of 52,953,416 shares at a price of RMB 12.88 per share, with a net amount of RMB 663,487,998.08 after deducting fees[78]. - The company has plans for future entrusted financial management activities[150]. - The company managed RMB 129,205,000 in entrusted financial management, with an overdue balance of RMB 17,614,000[149]. Employee Stock Ownership Plans - The company completed the third unlock of the second phase of its restricted stock incentive plan, with 9.461638 million shares unlocked on September 19, 2019[127]. - The first phase of the employee stock ownership plan had a total of 20,080,259 shares released from lock-up, accounting for 2.01% of the total share capital[129]. - The second employee stock ownership plan issued 6,830,046 shares, representing 0.65% of the company's total share capital[136]. - The company has implemented a share lock-up policy for executives and institutional investors to stabilize share prices post-IPO[191]. Market Position and Strategy - The company aims to accelerate new product development and registration processes, focusing on growth in gene engineering drugs and precision medicine[90]. - The company plans to enhance its marketing strategies, emphasizing brand influence and customer development to increase market share[91]. - The company is positioned to benefit from national pharmaceutical policy reforms, despite short-term industry challenges[89]. - The company aims to achieve sustainable development by leveraging its strengths in research, production, and marketing within the biopharmaceutical sector[90].

安徽安科生物工程(集团)股份有限公司 2019 年第三季度报告全文 安徽安科生物工程(集团)股份有限公司 2019 年第三季度报告 公告编号：2019-071 2019 年 10 月 1 安徽安科生物工程(集团)股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人宋礼华、主管会计工作负责人汪永斌及会计机构负责人(会计主 管人员)迟玲霞声明：保证季度报告中财务报表的真实、准确、完整。 2 安徽安科生物工程(集团)股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |----------------------------------------------------------------------|----------------------- ...

安徽安科生物工程(集团)股份有限公司 2019 年半年度报告全文 安徽安科生物工程(集团)股份有限公司 2019 年半年度报告 公告编号：2019-053 2019 年 08 月 1 安徽安科生物工程(集团)股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人宋礼华、主管会计工作负责人汪永斌及会计机构负责人(会计主 管人员)迟玲霞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |----------------------------------------------------------------------| | | | 报告期内，公司可能存在新药研究开发风险、国家政策变化风险、招标降 | | 价风险、产业整合风险、商誉减值风险、业务整合及规模扩大带来的集团化管 | | 理风险、募集资金使用不达预期风险等，有关风险因素内容已在本报告中第四 | | 节" ...

Financial Performance - Total revenue for Q1 2019 was CNY 347,288,318.05, representing a 24.16% increase compared to CNY 279,715,392.14 in the same period last year[3] - Net profit attributable to shareholders was CNY 66,343,681.00, an increase of 11.41% from CNY 59,547,879.35 year-on-year[3] - Net profit excluding non-recurring gains and losses was CNY 64,620,102.66, up 11.74% from CNY 57,830,373.43 in the previous year[3] - Basic earnings per share for the period were CNY 0.0665, reflecting an increase of 11.39% from CNY 0.0597 in the same period last year[3] - The company's total revenue for Q1 2019 reached RMB 347.29 million, an increase of 24.16% compared to the same period last year[13] - The net profit attributable to shareholders was RMB 66.34 million, reflecting an increase of 11.41% year-on-year[13] - The company reported a total profit of ¥74,432,200.06, up from ¥70,082,564.28 in the previous period, reflecting a growth of 5.0%[39] - The company’s total comprehensive income for the current period was ¥63,628,753.34, compared to ¥59,201,928.66 in the previous period, indicating an increase of 7.3%[41] Cash Flow and Assets - Net cash flow from operating activities decreased by 76.21% to CNY 9,352,712.78, down from CNY 39,318,162.87 in the same period last year[3] - The company's cash and cash equivalents at the end of the period saw a significant increase due to the completion of a private placement of shares, resulting in substantial fundraising[13] - Current assets total CNY 1.45 billion, an increase from CNY 756.46 million in the previous period[31] - The company’s cash and cash equivalents amount to CNY 600.04 million, compared to CNY 145.94 million at the end of the previous period[30] - The ending balance of cash and cash equivalents was CNY 600.04 million, up from CNY 88.72 million in the previous period[48] - The ending balance of cash and cash equivalents reached ¥504,176,464.10, up from ¥7,417,133.90 at the beginning of the period[50] Shareholding Structure - The total number of ordinary shareholders at the end of the reporting period was 42,002[6] - The largest shareholder, Song Lihua, held 26.52% of the shares, amounting to 278,576,096 shares[6] - The total number of shares held by executives is 335,870,839, with 20,209,709 shares under lock-up and 52,953,420 shares available for trading[12] - The first quarter report indicates a significant increase in user data, with a total of 206,072,670 shares held by key executives, reflecting a strong commitment to the company[9] - The company has implemented a stock incentive plan, with 9,910,676 shares under restricted stock incentives, indicating a focus on aligning executive interests with shareholder value[12] - The company plans to unlock 25% of the shares held by executives annually during their tenure, promoting long-term investment[9] - The overall shareholding structure includes various institutional investors, which may influence future strategic decisions and market expansion[11] - The company is committed to transparency in its shareholding and incentive structures, which is crucial for investor confidence[12] Research and Development - R&D expenses grew by 35.90% year-on-year, driven by accelerated progress in various R&D projects[13] - The company plans to enhance its R&D management and efficiency to mitigate risks associated with new drug development[14] - Research and development expenses increased to ¥21,266,350.57, a rise of 36.1% compared to ¥15,648,366.60 in the previous period[38] Investment and Financing - The company raised a total of RMB 682,039,998.08 through a non-public stock issuance, with a net amount of RMB 663,487,998.08 after deducting related expenses[18] - The stock issuance price was set at RMB 12.88 per share, with a total of 52,953,416 shares issued[21] - The total amount of raised funds is CNY 663.488 million, with CNY 185 million invested in the current quarter, achieving a 100% investment progress[25] - The company has invested CNY 103.81 million of its own funds in three projects, including CNY 33.25 million for the HER2 monoclonal antibody project, CNY 57.36 million for the growth hormone production line, and CNY 13.20 million for the precision medical innovation center[26] Risks and Challenges - The company is facing risks from national policy changes that may impact drug sales regions and prices, affecting overall profitability[15] - There is a risk of price reductions in bidding processes due to national healthcare reforms, which could impact future performance[16] - The company acknowledges potential goodwill impairment risks from acquisitions, which could adversely affect future earnings if performance targets are not met[17] - The company plans to enhance internal management and operational strategies to mitigate risks associated with industry integration and expansion[16] Employee Compensation and Stock Ownership - The company paid CNY 82.70 million in employee compensation, compared to CNY 63.94 million in the previous period, reflecting a rise in labor costs[47] - The company has completed the first phase of its employee stock ownership plan, with 20,080,259 shares released for trading[21] - The second phase of the employee stock ownership plan has 6,830,046 shares locked for 36 months post-issuance, ensuring stability in shareholding[10] - The company has a total of 20,080,259 shares under the first employee stock ownership plan, which is also subject to a 36-month lock-up period[10] Corporate Governance - The company is focused on maintaining a strong executive shareholding structure to enhance corporate governance and performance[9] - The company is committed to strengthening its corporate culture to ensure cohesive management across its diversified operations[16]

安徽安科生物工程(集团)股份有限公司 2018 年年度报告全文 安徽安科生物工程(集团)股份有限公司 2018 年年度报告 公告编号：2019-016 2019 年 03 月 1 安徽安科生物工程(集团)股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人宋礼华、主管会计工作负责人汪永斌及会计机构负责人(会计主 管人员)迟玲霞声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |-----------------------------------------------------------------------------------------| | | | 报告期内，公司可能存在新药研究开发风险、国家政策变化风险、招标降 | | 价风险、收购整合风险、商誉减值风险、业务整合及规模扩大带来的集团化管 | | 理风险等，有关风险因素内容已在本报告中第四节 " 经营情况 ...

安徽安科生物工程(集团)股份有限公司 2018 年第三季度报告全文 安徽安科生物工程(集团)股份有限公司 2018 年第三季度报告 安徽安科生物工程(集团)股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人宋礼华、主管会计工作负责人汪永斌及会计机构负责人(会计主 管人员)迟玲霞声明：保证季度报告中财务报表的真实、准确、完整。 2 安徽安科生物工程(集团)股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 公告编号：2018-082 2018 年 10 月 1 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,412,526,227.41 | 2,254,142,921.42 | | 7.03% | | 归属于上市公司股东的净资产 | 1,900,608,828.52 ...

安徽安科生物工程(集团)股份有限公司 2018 年半年度报告全文 安徽安科生物工程(集团)股份有限公司 2018 年半年度报告 公告编号：2018-061 2018 年 08 月 1 安徽安科生物工程(集团)股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人宋礼华、主管会计工作负责人汪永斌及会计机构负责人(会计主 管人员)迟玲霞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 报告期内，公司可能存在新药研究开发风险、国家政策变化风险、招标降 价风险、收购整合风险、商誉减值风险、业务整合及规模扩大带来的集团化管 理风险等，有关风险因素内容已在本报告中第四节"经营情况讨论与分析"之十、 公司面临的风险和应对措施部分予以描述，敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 ...

安徽安科生物工程(集团)股份有限公司 2018 年第一季度报告全文 安徽安科生物工程(集团)股份有限公司 2018 年第一季度报告 公告编号：2018-024 2018 年 04 月 1 安徽安科生物工程(集团)股份有限公司 2018 年第一季度报告全文 安徽安科生物工程(集团)股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人宋礼华、主管会计工作负责人汪永斌及会计机构负责人(会计主 管人员)迟玲霞声明：保证季度报告中财务报表的真实、准确、完整。 2 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 279,715,392.14 | 199,101,754.85 | 40.49% | | 归属于 ...